Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of KRT-232 or TL-895 in JAK Inhibitor–Naïve Myelofibrosis
2020-005642-42Phase 2Completed
- Sponsor
- Kartos Therapeutics
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navtemadlin and TL-895 in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (2 arms), sponsored by Kartos Therapeutics. Primary endpoint: Spleen volume response at Week 24. Started Mar 2021; status: completed.
02
Drugs
navtemadlinTL-895
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-005642-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005642-42.